Abstract
Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 1011-1019 |
Number of pages | 9 |
Journal | Immunotherapy |
Volume | 8 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2016 |
Keywords
- lung cancer
- meta-analysis
- nivolumab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology